Mirati 516-005
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Merck MK7339-012
Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC
Awaiting Activation
Merck MK7339-013
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Genentech BO42592
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Of Tiragolumab In Combination With Atezolizumab Plus Pemetrexed And Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed And Carboplatin/Cisplatin In Patients With Previously Untreated Advanced non-Squamous Non-Small Cell Lung Cancer
TRIO-US Diiachi Sankyo DS1062-A-U301
PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS